← All trials
NCT05955924
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2023
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2027
- First posted
- Jul 21, 2023
- Last posted
- Sep 26, 2023
- Enrollment
- 396
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- NOW FoodsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.